ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Engineering Morphological Anisotropy to Control the In Vivo Transport Dynamics, Clearance, and Biodistribution of Silica Nanocarriers.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Shape governs function across scales in nature, from streamlined bacteria to biconcave red blood cells that navigate capillary flow. Inspired by these bio-geometries, we explore how nanoscale anisotropy can be engineered to control the dynamic transport and biodistribution of synthetic nanocarriers in the body. We fabricate anisotropic silica nanocapsules with precisely tunable asymmetry to dissect shape effects on nano-bio interactions under physiological flow. Under shear flow in vitro, increasing anisotropy markedly reduced cellular uptake, whereas this effect was much less pronounced under static conditions, revealing strong flow-shape coupling. In vivo, highly anisotropic nanocapsules exhibit prolonged circulation, with a 2.8-fold longer half-life than spherical counterparts and significantly reduced sequestration by the liver, spleen, and circulating blood cells. Mechanistic analyses attributed these effects to decreased phagocytic internalization by Kupffer cells, splenic macrophages, and circulating monocytes. Computational fluid dynamics simulations corroborated this phenomenon, demonstrating that greater anisotropy shifts particle trajectories away from vessel walls toward the central flow stream, lowering the chances of cellular interception. Together, these results establish nanoscale anisotropy as a critical determinant of nanoparticle transport, immune recognition, and clearance under flow. Anisotropy engineering therefore provides a nature-inspired framework for designing long-circulating, immune-evasive nanocarriers with improved therapeutic performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.